Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling

Fig. 2

Inhibition of BCL10 causes differential cell cycle arrest and increases drug sensitivity in PDAC cell lines. a shBCL10 resulted in G2/M phase arrest in PANC-1 and AsPC-1 cells, but caused G1 phase arrest in BxPC-3. b The cell survival analysis showed that shBCL10 transfection significantly increased a dose-dependent inhibition of cell viability to gemcitabine (GEMZAR) treatment in PANC-1, AsPC-1, and BxPC-3 cells. c Similarly, shBCL10 transfection significantly increased a dose-dependent inhibition of cell viability to oxaliplatin (Oxali) treatment in PANC-1, AsPC-1, and BxPC-3 cells. The results are expressed for triplicates in each treatment group and measured each week. *p < 0.05; **p < 0.01; ***p < 0.001. PDAC pancreatic ductal adenocarcinoma

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us